Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading?

Logo poskytovatele

Varování

Publikace nespadá pod Ekonomicko-správní fakultu, ale pod Středoevropský technologický institut. Oficiální stránka publikace je na webu muni.cz.
Autoři

DOUBEK Michael ŠMÍDA Michal

Rok publikování 2015
Druh Článek v odborném periodiku
Časopis / Zdroj Expert Review of Hematology
Fakulta / Pracoviště MU

Středoevropský technologický institut

Citace
www http://www.tandfonline.com/doi/abs/10.1586/17474086.2015.1079123?journalCode=ierr20
Doi http://dx.doi.org/10.1586/17474086.2015.1079123
Obor Onkologie a hematologie
Klíčová slova CD20; CD52; chronic lymphocytic leukemia; monoclonal antibodies; resistance; therapy
Přiložené soubory
Popis Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in the western world and monoclonal antibodies (mAbs) are important part of CLL treatment. The goal of this article was to summarize current literature on the position of mAbs in CLL treatment and to mention factors influencing effectiveness of mAbs in CLL. Several new mAbs have been developed and investigated in CLL over the past few years. Mainly anti-CD20 monoclonal antibodies are still used routinely in CLL therapy. Unfortunately, the clinical application of mAbs needs to be further improved. Novel combinations and sequences of mAbs with other compounds need to be studied in clinical trials in order to increase overall response rate and prolong remission duration. Mechanisms of action of mAbs or mechanisms of resistance to mAbs have to be also investigated to predict effectiveness of mAb in particular patient. 2015 © Informa UK, Ltd.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.